Files and links (1)
Published, Version of Record (VoR)CC BY V4.0, Open
Journal article
Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial
GeroScience, v 41(6), pp 861-869
01 Dec 2019
PMID: 31761958
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Aging is a major risk factor for the majority of human diseases, and the development of interventions to reduce the intrinsic rate of aging is expected to reduce the risk for age-related diseases including cardiovascular disease, cancer, and dementia. In the skin, aging manifests itself in photodamage and dermal atrophy, with underlying tissue reduction and impaired barrier function. To determine whether rapamycin, an FDA-approved drug targeting the mechanistic target of rapamycin (mTOR) complex, can reduce senescence and markers of aging in human skin, an exploratory, placebo-controlled, interventional trial was conducted in a clinical dermatology setting. Participants were greater than 40 years of age with evidence of age-related photoaging and dermal volume loss and no major morbidities. Thirty-six participants were enrolled in the study, and nineteen discontinued or were lost to follow-up. A significant (P = 0.008) reduction in p16(INK4A) protein levels and an increase in collagen VII protein levels (P = 0.0077) were observed among participants at the end of the study. Clinical improvement in skin appearance was noted in multiple participants, and immunohistochemical analysis revealed improvement in histological appearance of skin tissue. Topical rapamycin reduced the expression of the p16(INK4A) protein consistent with a reduction in cellular senescence. This change was accompanied by relative improvement in clinical appearance of the skin and histological markers of aging and by an increase in collagen VII, which is critical to the integrity of the basement membrane. These results indicate that rapamycin treatment is a potential anti-aging therapy with efficacy in humans. Trial registration Identifier: NCT03103893.
Metrics
Details
- Title
- Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial
- Creators
- Christina Lee Chung - Drexel UniversityIbiyonu Lawrence - Drexel UniversityMelissa Hoffman - Drexel UniversityDareen Elgindi - Drexel UniversityKumar Nadhan - Drexel UniversityManali Potnis - Drexel UniversityAnnie Jin - Drexel UniversityCatlin Sershon - Drexel UniversityRhonda Binnebose - Drexel UniversityAntonello Lorenzini - University of BolognaChristian Sell - Drexel University
- Publication Details
- GeroScience, v 41(6), pp 861-869
- Publisher
- Springer Nature
- Number of pages
- 9
- Grant note
- Commonwealth of Pennsylvania, Commonwealth Universal Research Enhancement Program (CURE) Drexel University Coulter Foundation Drexel University College of Medicine Aging Initiative
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Biochemistry and Molecular Biology
- Web of Science ID
- WOS:000498200800001
- Scopus ID
- 2-s2.0-85075332695
- Other Identifier
- 991019168157004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Geriatrics & Gerontology